We identified CYP2C22 as a putative nitric oxide (NO)-regulated protein in a proteomic screen, and raised specific polyclonal antibodies to CYP2C22 to study its protein expression. We found that CYP2C22 is a liver specific protein that was not significantly induced by activators of the pregnane X receptor, constitutive androstane receptor or peroxisome proliferatoractivated receptor-α, but was down-regulated to <25% of control by the aryl hydrocarbon receptor agonist β-naphthoflavone in cultured rat hepatocytes. CYP2C22
INTRODUCTION
Nitric oxide (NO) has diverse physiological roles, including vasodilation and blood pressure regulation (Palmer et al., 1987) , neuronal communication (Dawson et al., 1992) , and pathogenic cell killing (Green et al., 1990) . In the latter case, NO is produced at high concentrations by the inducible nitric oxide synthase (NOS2) (Nussler and Billiar, 1993) , whose expression is induced via activation of toll-like receptors and cytokine receptors in cells of the innate immune system as well as in hepatocytes and other cell types (Nussler and Billiar, 1993) .
Activation of the immune system results in the down-regulation of many drug metabolizing enzymes (Aitken et al., 2006) and transporters (Cressman et al., 2012) in the liver, notably enzymes of the cytochrome P450 (P450) superfamily (Aitken et al., 2006) . Stadler et al (Stadler et al., 1994) first suggested that this down-regulation of P450 proteins and/or mRNAs by inflammatory mediators could be due to NO produced via NOS2 induction. While subsequent studies have revealed that this is not true for all, or even perhaps most P450s (Sewer and Morgan, 1997; , various studies have suggested a role for NO in the regulation of CYP2B enzymes (Khatsenko et al., 1993; Carlson and Billings, 1996; Khatsenko et al., 1997) . We have shown that NO produced by interleukin-1β (IL-1β) or lipopolysaccharide stimulation of hepatocytes causes ubiquitin-dependent proteasomal degradation of the rat phenobarbital-inducible P450 CYP2B1 (Ferrari et al., 2001; This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #209841 6 al., 2008; Sun et al., 2012) . The related human enzyme CYP2B6 also undergoes downregulation at the protein level in response to NO (Aitken et al., 2008) .
The mechanism whereby NO triggers the degradation of CYP2B1 is unknown.
Both iron regulatory protein 2 (Kim et al., 2004) and alkylguanine DNA-alkyltransferase (Wei et al., 2010) undergo proteasomal degradation triggered by S-nitrosylation of critical cysteines. Although CYP2B1 can be nitrosylated by NO donors in vitro , changes in nitrosylation state of the protein have not been demonstrated in a cellular context. As another approach, we have been searching for other P450
enzymes that undergo NO-dependent degradation. We described earlier an isobaric tags for relative and absolute quantitation ( iTRAQ)-based proteomic approach to this problem, and we used it to identify rat CYP3A enzymes as additional NO targets (Lee et al., 2009 ). The primary objective of the current study was to investigate the regulation by NO of an additional P450 enzyme identified in the same proteomic study, CYP2C22.
During the course of the current work, CYP2C22 was identified as a putative Vitamin A-regulated gene by microarray analysis of livers from Vitamin A-sufficient anddeficient rats (McClintick et al., 2006) . Qian et al replicated this observation using in situ hybridization (Qian et al., 2010) , and they demonstrated via reverse transcriptase (RT)-PCR that CYP2C22 mRNA is expressed predominantly in liver. CYP2C22 mRNA was induced by all-trans-retinoic acid (atRA) and the synthetic retinoic acid receptor (RAR) agonist Am580 in H-4-II-E rat hepatoma cells (Qian et al., 2010) . Transient transfection of luciferase reporter constructs were used to identify a retinoic acid response element JPET #209841 7 in the distal promoter region of the CYP2C22 gene. Moreover, CYP2C22 expression in HEK293T cells conferred higher retinoic acid metabolizing activity upon those cells (Qian et al., 2010) , identifying CYP2C22 as a retinoic acid hydroxylase. Therefore, a second objective of our work was to confirm the regulation of CYP2C22 by retinoids at the protein expression level, and to investigate the regulation of this enzyme by classical inducers of hepatic P450s.
In this manuscript, we describe the preparation of specific polyclonal antibodies to CYP2C22, and use them to investigate the regulation of this poorly understood enzyme by nitric oxide, IL-1β and atRA, as well as by prototypical nuclear receptor agonists. LM-CMAC) was purchased from Molecular Probe (Grand Island, NY). 4-OH-RA was synthesized as described previously (Lutz et al., 2009; Shimshoni et al., 2012) . Anti-CYP2B1 was kindly provided by Dr. James Halpert (University of California, San Diego, CA). Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was acquired from Millipore (Billerica, MA) , and anti-NOS2 and anti-Annexin VI antibodies were purchased from Santa Cruz (Santa Cruz, CA) respectively. Anti-CYP2C11
MATERIALS AND METHODS

Materials
antibody was generated in our laboratory as described previously (Morgan et al., 1985) .
Antibody production and peptide blocking experiment
Peptide synthesis and antibody production were carried out by Open Biosystems, Inc (Huntsville, AL). The CYP2C22-specific peptide corresponds to residues 366 to 390 (24 amino acids, PRKTTQDVEFRGYHIPKGTSVMAC). Antibodies were raised in two rabbits, which were bled to measure antibody production after each injection. After the third injection of the peptide, a final bleed was performed, and then CYP2C22 antisera were prepared. To determine the specificity of the CYP2C22 antibody, various amounts of the immunogenic CYP2C22-specific peptide were immobilized by adsorption on nitrocellulose paper, which was then blocked with 5% non-fat dry milk for 1 h. After washing 3 times with washing buffer (10 mM potassium phosphate, pH7.4; JPET #209841 9 0.05% Tween 20; 1.15% KCl; 0.02% sodium azide), 5 ml of 1,000-fold diluted polyclonal antibody sera were incubated overnight with the nitrocellulose paper at 4 °C to immobilize CYP2C22-specific antibody. Unbound antibody solution was then taken for Western blotting to determine the specificity of antibody.
Rat hepatocyte isolation, treatment and harvesting
Rat hepatocytes were isolated by a two-step in situ collagenase perfusion procedure with minor modifications, which are described below. The procedure was approved by the Emory University Institutional Animal Care and Use
Committee. Male F344 rats (200-250 g) were anesthetized with ketamine-xylazine solution, and then the liver was perfused with 300-400 ml of Krebs-Ringer bicarbonate buffer for 8-10 min. This was followed by perfusion with 0.3 mg/ml collagenase type IV (Sigma) for 10 min. The liver was harvested and gently chopped to release cells, which were filtered through 90-and 200-μm meshes. Hepatocytes were cultured under conditions, and treated at time points, that yield optimal constitutive (Liddle et al., 1992) and phenobarbital-inducible (Sidhu et al., 1993) cytochrome P450 expression. Cells were plated on collagen plates with plating medium containing 10% FBS, and 3 h later cells were overlaid with new media containing Matrigel (0.234 mg/ml, BD Biosciences).
After 24 h the medium was changed to Williams E medium containing 10 mM Hepes, 
Preparation of rat liver S9 and microsomal fractions, and immunoblotting
Rat livers were homogenized in ice-cold homogenization buffer (0.1 M potassium phosphate buffer, pH 7.4, containing 0.125 M potassium chloride, 1.0 mM EDTA, and a protease inhibitor mixture (aprotinin, bestatin, E-64, leupeptin and pepstatin (Sigma P83400)) and then centrifuged at 10,000 × g at 4 o C for 20 min to obtain the S9 fraction.
For preparation of microsomes, the S9 fraction was centrifuged at 160,000 × g for 45 min at 4 o C. The supernatant from ultracentrifugation was considered the cytosolic fraction, and the pellet was washed with cold microsome storage buffer (0.25 M sucrose containing protease inhibitor mixture) and homogenized in the same buffer.
SDS-PAGE and Western blotting were carried out as described by Lee et al. (Lee et al., 2008 Lentivirus was generated with a second generation vector system as described by Naldini et al (Naldini et al., 1996) . Lv-CMV-2C22 or pLV-CMV-GFP-U3Nhe along with 
Hepatocyte retinoic acid metabolism
All incubations were done under red light, and were conducted as duplicates of each of the biological triplicates in the treatment group. The incubations contained 60 μ g of rat hepatocyte S9 protein, 1 mM NADPH and 2 µM atRA in 100 µl of 100 mM potassium phosphate buffer (pH 7.4). After 5 minutes at 37 ºC, the reactions were
initiated by the addition of NADPH and allowed to proceed at 37 ºC for 20 mins. A control incubation without NADPH was conducted for each group to assure that 4-OH-RA formation was NADPH dependent. The reactions were terminated with 100 µl ice cold acetonitrile containing the internal standard ( 
Cellular calpain activity assay
Calpain activity was measured using a fluorescence-based assay with Boc-LM-CMAC as substrate (Rosser et al., 1993) . Assay buffer (1 mM Na 2 HPO 4 , 137 mM NaCl, 5 mM KCl, 0.5 mM MgCl 2 , 2 mM CaCl 2 , 10 mM glucose, and 10 mM Hepes, pH 7.4; (Donato et al., 2004) ) containing Boc-LM-CMAC (25 μM) was added to fully confluent CYP2C22 lentivirus-transduced HuH7 cells grown in 12-well plates, and incubated for 20 min. CMAC released from the cell due to calpain cleavage of the substrate was measured in the media with a fluorometer (Excitation λ, 380 nm; Emission λ, 455 nm).
Statistical analyses.
Data are expressed as the mean ± standard error of the mean. Differences between groups were calculated either by T-test or by oneway ANOVA followed by Dunnett's test or Tukey's test, as appropriate for each experimental design.
RESULTS
Discovery of CYP2C22 as a putative NO-regulated protein.
We described previously how we used iTRAQ proteomic technology to identify proteins that were rapidly down-regulated in a NO-dependent manner by interleukin-1β
(IL-1β) in cultured rat hepatocytes (Lee et al., 2009) . From 229 total proteins identified, three were predicted to be regulated by NO. Two of them, CYP2B1/2 and CYP3A1/2 have been demonstrated to undergo NO-dependent proteasomal degradation in response to IL-1 and NO donors Lee et al., 2009 was CYP2C22, which was identified from peptides KLPPGPTPLPIFGNILQVGVK and RFSLMVLR, having average abundances that were 1.9-fold lower in the samples exposed to NO (data not shown).
CYP2C22 antibodies and their characterization
As discussed earlier, CYP2C22 has been described as a RAR-regulated mRNA in rat liver in vivo and in rat hepatoma cells, although nothing is known about its protein expression. Alignment of the amino acid sequence of CYP2C22 with those of other rat CYP2C subfamily members revealed the region from amino acids 366 to 390 to be one of greatest divergence, and therefore this peptide was used to raise antibodies in rabbits. As shown in Fig. 1A , the antibodies from rabbit #96 recognized a single protein band in rat hepatocyte lysates, rat liver S9 fraction and rat liver microsomes, and this was abolished by preincubation of the serum with the peptide antigen bound to nitrocellulose paper. Antibodies from rabbit #97 recognized the same band, and upon overexposure two minor bands of lower molecular weight. Preincubation of #97 serum with the antigen peptide abolished all of the bands (even longer exposure revealed one faint band of the same MW as CYP2C22, which was only seen in liver S9 fractions).
The #97 antibody was selected for use going forward, as it had a higher titer. The #96
and #97 antibodies failed to recognize rat CYP2B1, 2C6, 2C11, 2C12, 2D1, 2D2 or 3A2 (Fig. 1B) , or human CYPs 1A1, 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4 (not shown). Together, these experiments establish the specificity of the antibodies for CYP2C22 in rat liver microsomes and hepatocyte lysates.
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While CYP2C22 mRNA was reported to be restricted to rat liver (with very lowlevel expression in brain (Qian et al., 2010) ), the expression of CYP2C22 protein is not known. Western blotting revealed that CYP2C22 protein expression is restricted to the liver, with undetectable levels in brain, lung, heart, spleen, kidney or small intestine (Fig.   1C ), mRNA expression in these tissues was at least 1,000-fold lower than liver (Fig. 1D ).
CYP2C11 expression, included for comparison, was also liver-specific.
Regulation by atRA
CYP2C22 protein was significantly induced 1.8-fold within 6h of 5 μM atRA treatment of cultured hepatocytes, reaching 3.2-3.5-fold of control at 18-24 h of incubation ( Fig. 2A,B) . CYP2C22 mRNA was rapidly induced by atRA, by 3.6-fold at 6 h and reaching a maximum of 7.4-fold within 12 h (Fig. 2B) . The induction of CYP2C22 protein lagged only slightly behind of its mRNA. atRA induced CYP2C22 protein with an approximate EC 50 in the 10 -100 nM range (Fig. 2C ). CYP2C22 mRNA was induced by atRA in a similar concentration range. Induction of the mRNA for the known RAR target genes CYP26B1 and CYP26A1 had similar kinetics to those of CYP2C22, although their maximal extent of induction were much higher at 480-and 74-fold, respectively (Fig. 2B) . Induction of the CYP26 mRNAs was only significant at atRA concentrations >1 μM (Fig. 2D) . Again, the magnitude of CYP26B1 induction was about 10-fold higher than that of CYP26A1.
Regulation by nuclear receptor agonists
This article has not been copyedited and formatted. The final version may differ from this version. clofibrate (a peroxisome proliferator-activated receptor-α (PPARα) agonist). We used concentrations that we and others determined previously were sufficient to induce prototypic target genes in rat hepatocytes.
PCN caused significant induction of CYP2C22 mRNA after 3 days, while dexamethasone, and clofibrate trended in the same direction. However, none of these agents affected the levels of CYP2C22 protein (Fig. 3A, B) . Phenobarbital had no effect on CYP2C22 mRNA or protein, whereas β-naphthoflavone down-regulated both mRNA and protein to 38% and 24% of control levels, respectively (Fig. 3A, B) . The effects of β-naphthoflavone and clofibrate on CYP2C22 protein were further investigated with respect to time course (results not shown). The down-regulation by β-naphthoflavone was already manifested after 24 h of treatment, whereas clofibrate produced a small (12%) but significant suppression at 3 days only.
Down-regulation of CYP2C22 by IL-1β via NO generation
Incubation of rat hepatocytes with 5 ng/ml IL-1β resulted in a down-regulation of CYP2C22 protein, which became significant within 8 h of treatment and reached a nadir at 12 h (Fig. 4A,B ). This corresponded with the time course of induction of NOS2, and the detection of nitric oxide products (NOx) in the culture medium. Notably, NOS2
expression and the rate of NOx production declined significantly between 12 and 24 h after treatment, during which time CYP2C22 protein expression began to recover. The rapid decline in CYP2C22 protein expression occurred in the absence of any significant effect of IL-1β on CYP2C22 mRNA levels (Fig. 4C) .
The NOS inhibitor L-NAME effectively blocked IL-1β-evoked NO production in the hepatocytes, and at the same time blocked the down-regulation of CYP2C22 ( Fig.   4D -F). We performed this experiment with and without phenobarbital pretreatment of the cells, because our proteomic experiment in which we identified CYP2C22 as a putative NO-regulated protein was performed in phenobarbital-treated cells. The same results were seen regardless of the pretreatment (Fig. 4D-F ). The time courses of the effects of NOC18 on CYP2C22 mRNA and protein was investigated. While levels of both CYP2C22 mRNA and protein changed over time in the control cells, NOC18 caused a marked down-regulation of CYP2C22 protein at every time point studied (3 -24 h), while producing no effect on the corresponding mRNA levels (Fig. 5A,B) . Almost complete suppression of CYP2C22 was achieved with 1 mM NOC 18, and the IC 50 was approximately 300-500 μM (Fig. 5C, D) .
An NO donor mimics the effect of IL-1β
Since CYP2C22 is a retinoic acid-metabolizing enzyme in rat liver, we next determined the effect of NO donor treatment on the retinoic acid metabolizing activities of hepatocytes. Cells were treated with 5 ng/ml IL-1β or 500 μM NOC18 for 12 h, or 500μM DPTA for 6 h, then the cells were harvested and S9 fractions were prepared.
The treatments decreased atRA 4-hydroxylation by 60-80% indicating significantly decreased CYP2C22 activity (Fig. 5E ). The efficacies of these treatments on CYP2C22 protein levels were verified by Western blotting (Fig. 5F ), and the declines in CYP2C22
protein contents of the microsomes were correlated with comparable reductions in retinoic acid metabolism (Fig. 5E, F) . The decreased CYP2C22 protein was reflected in significantly decreased atRA hydroxylation. We note a faint lower molecular weight band detected by the CYP2C22 antibody in this experiment. Its identity is unknown, and it is only detected in some experiments.
Stimulation of CYP2C22 protein degradation by NO donors
CYP2C22 protein down-regulation by NOC18 was maintained in the presence of the protein synthesis inhibitor cycloheximide (Fig. 6A,B) . A time course analysis with DPTA as the NO donor showed that the DPTA reduced the half-life of CYP2C22 protein from 8.7 h to 3.4 h (Fig. 6C ).
This article has not been copyedited and formatted. The final version may differ from this version. To determine the effect of proteasome inhibition on CYP2C22 down-regulation, we performed the experiments in the presence of 1 mM phenobarbital to allow for expression of CYP2B1, which we have shown is degraded via the proteasome following IL-1β or NOC-18 exposure of the cells. Hepatocytes were treated with the proteasome inhibitors MG132 or bortezomib 4 h after initiation of IL-1 treatment of the cells. As we demonstrated previously, these treatments effectively blocked CYP2B1 protein downregulation (Fig. 7A,B) while not affecting NO production by the cells (Fig. 7C) . However, proteasome inhibition failed to block the down-regulation of CYP2C22 (Fig. 7A,B) . We verified that proteasome inhibitors also did not block CYP2C22 down-regulation by IL-1β in the absence of phenobarbital (data not shown). Proteasome inhibition also failed to block the down-regulation of CYP2C22 by DPTA (Fig. 7D ). Brefeldin A (inhibits endoplasmic reticulum to Golgi transport as well as endosomal trafficking (LippincottSchwartz et al., 1991) (Strous et al., 1993) ), also failed to affect CYP2C22 downregulation (Fig. 7D) .
In experiments not shown, we tested several different calpain and lysosomal protease inhibitors for their abilities to block the IL-1, NOC18 or DPTA-evoked degradation of CYP2C22 in hepatocytes at various time points, and were unable to detect any significant effect. We also tested whether oxidative signals other than NO could down-regulate CYP2C22 and CYP2B1. Phenobarbital-induced hepatocytes were treated with 5 mM H 2 O 2 , NO donors or IL-1β. The NO donors and IL-1β down-regulated the P450 proteins as seen previously, but H 2 O 2 failed to do so in the presence or absence of the catalase inhibitor aminotriazole (Fig. 7E, F) . To investigate further the proteolytic enzymes responsible for CYP2C22 downregulation, we established a HuH7 cell line expressing CYP2C22 using a lentiviral vector. As shown in Fig 8A, DPTA down-regulated CYP2C22 protein expression to 30% of control in these cells, but the calpain inhibitors E64d, MDL-2180 or ALLM failed to attenuate this down-regulation. MDL-2180 or ALLM effectively inhibited calpain activity, whereas E64d was less effective (Fig. 8B) . The lysosome inhibitors chloroquine and NH 4 Cl also failed to block CYP2C22 down-regulation, but effectively inhibited lysosomal degradation of Annexin VI (Cuervo et al., 2000) as observed by a significant increase in Annexin VI protein in the cells (Fig. 8C ).
DISCUSSION
Our data establish CYP2C22 as a third P450 protein targeted by NO-mediated degradation in rat hepatocytes, based on the prevention of IL-1β-mediated suppression by NOS inhibitors; suppression of protein expression in the absence of significant effects on the cognate mRNA; and, its rapid down-regulation by NO donors in the presence of the protein synthesis inhibitor cycloheximide. Using DPTA, an NO donor with a chemical half-life in aqueous solution of 3 h (Hrabie et al., 1993) , the half-life of CYP2C22 was reduced by 60% to 3.4 h. While the kinetics of down-regulation could be fitted to an exponential curve (R=0.964), the data gave some indication of a biphasic decay (Fig 6C) . specific to NO and is not reproduced by oxidant stress caused by application of hydrogen peroxide in the presence or absence of catalase inhibition.
The down-regulation of CYP2C22 by IL-1β and the NO donors DPTA and NOC18 was accompanied by similar changes in the retinoic acid hydroxylase activities of the cells, supporting the reported finding of CYP2C22 as a retinoic acid hydroxylase (Qian et al., 2010) . This significant role of CYP2C22 in atRA metabolism is most likely due to the fact that CYP26 enzyme expression is low in the absence of atRA treatment as shown in human hepatocytes and HepG2 cells (Tay et al., 2010) . The remaining atRA hydroxylation activity in the IL-1 and NO donor-treated hepatocytes could be due to the contribution of CYP26 enzymes to atRA hydroxylation.
Unlike CYP2B1 (Sun et al., 2012) and CYP3A (Lee et al., 2009) however, the down-regulation of CYP2C22 by NO could not be inhibited by proteasome inhibitors. Lysosomal degradation is the main route of degradation of CYP2B and some other P450 enzymes in their native states (Ronis et al., 1991 ) (Roberts, 1997 ) (Liao et al., 2005 ), but we found that the lysosomal inhibitors NH 4 Cl and chloroquine; as well as three different calpain inhibitors all failed to inhibit CYP2C22 down-regulation.
Therefore, we conclude that CYP2C22 degradation in response to NO proceeds via a novel pathway. The protein is not being trafficked to a different cellular compartment, since whole cellular lysates were used. Also, we have not detected the appearance of any lower molecular weight bands during CYP2C22 degradation, even on overexposed blots from cells treated with proteasome inhibitors. The possibility that CYP2C22 was being cleaved in the antigenic domain (amino acids 366-390) was also investigated. In experiments not shown, we determined that a different polyclonal antibody raised to the entire CYP2C11 protein recognizes a protein in rat hepatocytes that undergoes rapid NO-dependent down-regulation similar to that of CYP2C22. It has been documented that CYP2C22 expression increases when hepatocytes are cultured, while CYP2C11 declines (Emi et al., 1990 ). Since we have determined that CYP2C11 is not an NO-responsive protein (Sewer and Morgan, 1997) (Lee et al., 2009) , we conclude that this CYP2C11 antibody detects primarily CYP2C22 in these cultures. Using this polyclonal CYP2C antibody, we were also unable to detect discreet cleavage products in overexposed blots from cells treated with proteasome inhibitors and NO donors. Clearly the CYP2C11 antibody recognizes additional CYP2C epitopes to the specific CYP2C22 antibody. Therefore, we conclude it to be unlikely that the disappearance of the protein is due to a peptidase making a discreet cut between amino acids 366-390.
CYP2C11 and CYP2C22 share 61% amino acid identity (298/489), yet CYP2C22 undergoes NO-stimulated degradation whereas CYP2C11 does not. The contrasting behaviors of these highly related proteins may provide a strategy from which to identify structural features that confer response to NO. As mentioned above, cysteine nitrosylation sensitizes iron regulatory protein 2 and alkylguanine DNA-alkyltransferase (Kim et al., 2004 ) (Wei et al., 2010) to proteasomal degradation. On the other hand, tyrosine nitration of CYP2B1 on Y190 is causal for its catalytic inactivation by degradation. CYP2C22 has four cysteine residues (C13, C55, C164 and C389) and six tyrosine residues (Y78, Y151, Y219, Y223, Y265 and Y315) that are not present in CYP2C11. Human CYP2C8, 2C9 and 2C19 share 60.7, 62.0 and 61.6% amino acid identity with CYP2C22. C164 and C389 are present in all three human CYP2Cs, and C13 is present in CYP2C9 and 2C19. None of the six tyrosines absent from 2C11 are present in the human CYP2C enzymes. The contributions of these residues to NOmediated degradation are currently under investigation. However, it must also be considered that larger structural features could be involved in the susceptibility to degradation.
Using antibodies specific to CYP2C22, we demonstrated that its tissue distribution is the same as reported previously for its mRNA specificity (Qian et al., 2010) . In a rat hepatoma cell line, CYP2C22 mRNA was induced approximately 10-fold by 100 nM -1μM atRA, while higher concentrations were not tested (Qian et al., 2010) .
Our data in primary hepatocytes is in good agreement with this finding. Interestingly CYP2C22 mRNA and CYP26B1 levels began to decline between 12 h and 24 h of treatment, possibly reflecting increased atRA metabolism due to the induction of these proteins (Isoherranen, N et al, unpublished data) . As a consequence, CYP2C22 protein levels never reached the same magnitude of induction as CYP2C22 mRNA.
Nevertheless, CYP2C22 protein began to be induced only 3 h after the mRNA was first seen to increase, consistent with our determination of a half-life of only 8.7 h for the protein in the absence of NO. Westin et al found that the closely related CYP2C7 mRNA was induced by atRA in rat hepatocytes and was partially dependent on atRA metabolism (Westin et al., 1993 ) (Westin et al., 1997) . However, significant induction was only observed at atRA concentrations >1μM in hepatocytes (Westin et al., 1993) Further research will be needed to determine if such a mechanism could explain the rapid down-regulation of CYP2C22 mRNA by β-naphthoflavone.
We showed previously that, like rat CYP2B1, human CYP2B6 protein undergoes NO-dependent down-regulation in human hepatocytes (Aitken et al., 2008) . an NO donor. Hepatocytes were treated with medium (Con) or 500 μM DPTA for 5 h in the presence or absence of bortezomib (10 μM), MG132 (20 μM), or brefeldin A (Bre, 10 μM). E, Effect of hydrogen peroxide on CYP2C22 and CYP2B expression.
Hepatocytes were pretreated with phenobarbital as described for panel A, and then treated with control medium (Con) or H 2 O 2 (5 mM) with or without aminotriazole (AT, 25 mM) for 5h, or with NOC18 (500 μM, 12 h), DPTA (500 μM, 6 h), or IL-1 (5 ng/ml, 12 h).
The cells were harvested at the same time and the levels of CYP2C22 and CYP2B
proteins were assessed by Western blotting. F, Quantitative analysis of the data in panel E. *, significantly different from control, p<0.05 Dunnett's test (n=3). 
